Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71305/Aktiencheck_Vidac_120723.001.png
Erstklassige Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. Neuer 208% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Erstkl. Studienergebnisse im Kampf gegen Hautkrebs - Massives Kaufsignal. 208% Biotech Hot Stock nach 31.205% mit Amgen

 

12.07.23 08:02

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

Accolade: A Rising Personalized AI-Powered Healthcare Platform: https://www.marketbeat.com/logos/articles/med_20230709131618_chart-accd.jpg
Accolade: A Rising Personalized AI-Powered Healthcare Platform

Accolade Inc. (NASDAQ: ACCD) is an artificial intelligence (AI) powered healthcare platform that provides personalized healthcare guidance for employers and workers. The platform helps people

3 Stocks that Analysts Continue to Upgrade into Earnings Season: https://www.marketbeat.com/logos/articles/med_20230710103919_3-stocks-that-analysts-continue-to-upgrade-into-ea.jpg
3 Stocks that Analysts Continue to Upgrade into Earnings Season

One simple signal that investors can use to decide if a stock is likely to move higher is to look at analyst sentiment. An analyst is a market professional employed by either funds that buy

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi: https://www.marketbeat.com/logos/articles/med_20230707134150_biogen-shares-fall-after-fda-approval-of-alzheimer.jpg
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. (NASDAQ: BIIB) swooned 2.88% in heavy trading volume following news of full

Pfizer Just Invested $25 million In This Biotech: https://www.marketbeat.com/logos/articles/med_20230707085820_pfizer-just-invested-25-million-in-this-biotech.jpg
Pfizer Just Invested $25 million In This Biotech

Shares of Caribou Biosciences (NASDAQ: CRBU) were up 45% yesterday after Pfizer (NYSE: PFE) made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million

Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy: https://www.marketbeat.com/logos/articles/med_20230706072115_inspire-medical-up-15-after-breakout-analysts-say.jpg
Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy

Inspire Medical Systems (NYSE: INSP) is up nearly 15% since breaking out of cup-with-handle base on May 3. The base’s buy point was above $277.18, which you can see on the Inspire Medical Systems

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac : https://www.irw-press.at/prcom/images/messages/2023/71224/AC_VidacPharma_050723.001.png
Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 217% mit Biotech Aktientip Vidac

Eilt: Erstklassige Studienergebnisse im Kampf gegen Hautkrebs. Neuer 217% Biotech Hot Stock nach 134.452% mit Biogen

 

05.07.23 08:17

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/71203/Acresearch040723_01.001.png
Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)

Eilt: Sensationelle Studienergebnisse - Massives Kaufsignal. Neuer 224% Biotech Aktientip nach 31.205% mit Amgen ($AMGN)

 

04.07.23

AC Research

 

London (www.aktiencheck.de, Anzeige)

 

 

Drugmaker GSK: Becoming a Healthier Value Stock: https://www.marketbeat.com/logos/articles/med_20230627104026_drugmaker-gsk-is-becoming-a-healthier-value-stock.jpg
Drugmaker GSK: Becoming a Healthier Value Stock

Like most stocks during the dot-com bubble, GSK PLC (NYSE: GSK) partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceuti

PetVivo Sales Spryng Higher on Injectable OA Relief for Pets: https://www.marketbeat.com/logos/articles/med_20230625124449_chart-petv.jpg
PetVivo Sales Spryng Higher on Injectable OA Relief for Pets

Developmental biomedical device company PetVivo Holdings Inc. (OTCMKTS: PETV) makes pet medical devices and therapeutics. What kind of medical devices would pets need? Pacemakers? Artificial hearts

Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?): https://www.marketbeat.com/logos/articles/med_20230627075714_sarepta-therapeutics-gets-fda-nod-drops-warning-or.jpg
Sarepta Therapeutics Gets FDA Nod, Drops Warning (or Opportunity?)

On May 15, Sarepta Therapeutics Inc. (NASDAQ: SRPT) learned that its treatment for Duchenne muscular dystrophy (DMD) was recommended for approval by the Food and Drug Administration (FDA)

Agilent Technologies Stock: Ready to Rise off the Floor: https://www.marketbeat.com/logos/articles/med_20230618154044_chart-a.jpg
Agilent Technologies Stock: Ready to Rise off the Floor

Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment.

It counts

DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth: https://www.marketbeat.com/logos/articles/med_20230621092054_dexcom-clears-base-wall-street-eyes-double-digit-e.jpg
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth

You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc.

Medical Stocks Waters, Agilent, Illumina Show Growth Potential: https://www.marketbeat.com/logos/articles/med_20230620074442_medicals-stocks-waters-agilent-illumina-show-growt.jpg
Medical Stocks Waters, Agilent, Illumina Show Growth Potential

Investors seeking growth often have no choice other than paying up for a stock with strong potential. However, there are some stocks that appear to be trading at low valuations relative to their

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand: https://www.marketbeat.com/logos/articles/med_20230616065107_surgical-centers-med-tech-stocks-up-on-pent-up-sur.jpg
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. (NYSE:

Bullish or Bearish? Vetting Animal Health Care Stocks: https://www.marketbeat.com/logos/articles/med_20230616064027_bullish-or-bearish-vetting-animal-health-care-stoc.jpg
Bullish or Bearish? Vetting Animal Health Care Stocks

Dogs and cats were among the biggest beneficiaries of the pandemic thanks to more attention from housebound pet owners. Pet adoption trends also skyrocketed. 

As Fido and Fluffy were spoiled more

Humana's Fall Creates A Rare dip Buying Opportunity: https://www.marketbeat.com/logos/articles/med_20230615101220_humanas-fall-creates-a-rare-dip-buying-opportunity.jpg
Humana's Fall Creates A Rare dip Buying Opportunity

Investors are facing one of the rarest cases in financial markets, where a deeply entrenched enterprise operating in one of the most 'defensive' sectors has left a pain trail following a 15.3%

DarioHealth is an AI-Powered Digital Therapeutics Play: https://www.marketbeat.com/logos/articles/med_20230611133641_chart-drio.jpg
DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five

Novartis Stock Screams Value After Chinook Therapeutics Buyout: https://www.marketbeat.com/logos/articles/med_20230613065942_novartis-stock-screams-value-after-chinook-therape.jpg
Novartis Stock Screams Value After Chinook Therapeutics Buyout

Don’t be fooled by the fact that Novartis AG (NYSE:NVS) is trading near an all-time high. The Swiss pharmaceutical giant is still a good value.

That value proposition took a huge step forward on